Pacira BioSciences
PCRX
180 hedge funds and large institutions have $1.35B invested in Pacira BioSciences in 2016 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 66 increasing their positions, 51 reducing their positions, and 37 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
49% more call options, than puts
Call options by funds: $24.8M | Put options by funds: $16.6M
29% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 51
2% less capital invested
Capital invested by funds: $1.38B → $1.35B (-$28.8M)
3% less first-time investments, than exits
New positions opened: 36 | Existing positions closed: 37
2% less funds holding
Funds holding: 183 → 180 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$39.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$30.2M |
| 3 |
HM
HealthCor Management
New York
|
+$19.4M |
| 4 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$18.1M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$13.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$49.6M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$41.3M |
| 3 |
Millennium Management
New York
|
-$24.3M |
| 4 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$21.6M |
| 5 |
HCM
Hoplite Capital Management
New York
|
-$20.4M |
PCRX Hedge Fund Activity: Q3 2016 in Review
180 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q3 2016, worth a combined $1.35B — down 2.1% from $1.38B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of PCRX and 36 opened new positions — a net loss of 1 holder — while 51 trimmed existing stakes and 66 added.
The largest buyer was Macquarie Group, adding an estimated $39.8M. The largest seller was Fidelity Investments, cutting an estimated $49.6M.
- 180 institutional investors held Pacira BioSciences (PCRX) as of Q3 2016, down from 183 in Q2 2016.
- Funds reported $1.35B of Pacira BioSciences stock for Q3 2016, down 2.1% quarter-over-quarter.
- 36 funds opened new Pacira BioSciences positions in Q3 2016 and 37 closed out, a net change of -1 holder.
- The largest Pacira BioSciences buyer in Q3 2016 was Macquarie Group, an estimated $39.8M added.
- The largest Pacira BioSciences seller in Q3 2016 was Fidelity Investments, an estimated $49.6M sold.
Based on aggregated 13F filings for Q3 2016.